Week40, 2023
- **Viruses, illness, and deaths:** Seasonal influenza activity remains low nationally; 1.1% of respiratory specimens tested positive, with influenza A being the most common type. 0.05% of deaths were attributed to influenza this week. One pediatric death from the 2022-2023 season was reported.  
- **U.S. virologic surveillance:** Clinical labs reported 1.1% positivity, stable from the previous week. Influenza A comprised 60.4% of specimens, and Influenza B 39.6%. Public health labs found 86.2% of specimens were influenza A, primarily A(H1N1) (90.9%), and 13.8% were influenza B (Victoria lineage noted).  
- **Cumulative hospitalization rate:** The cumulative hospitalization rate was 0.1 per 100,000, stable across all age groups.  
- **Trends of deaths attributed to influenza:** Influenza-attributed deaths remain minimal (0.05%) and stable compared to the previous week.  
- **Percentage of Influenza A and B:** Influenza A dominated in both clinical (60.4%) and public health labs (86.2%).  
- **Novel influenza virus like COVID-19:** No novel influenza viruses such as SARS-CoV-2 were reported this week.  
- **Vaccination trends:** CDC recommends everyone aged 6 months and older receive flu vaccination by the end of October. Antiviral treatments are emphasized for flu illness.  
- **Outpatient respiratory illness visits:** 2.2% of healthcare visits nationwide were for ILI, below the national baseline of 2.9%. Region 9 showed an increase in activity, while Region 2 experienced a decrease. Most regions remain stable, with only one jurisdiction reporting moderate ILI activity.  
- **Expectation of flu activity from CDC:** Influenza activity is expected to remain low but may increase as the season progresses.  
- **Other key factors:** Multiple respiratory viruses, including influenza, COVID-19, and RSV, are co-circulating. Jurisdiction-level activity: 6 jurisdictions reported low activity and 47 had minimal activity.  

